Evidence-based pharmacotherapy for cerebral vasospasm

Neurological Research

Volumn 31, Issue 6, 2009, Pages 615-620

  Deshaies, Eric Michael ^a,b   Boulos, Alan S ^a   Drazin, Doniel ^a   Popp, A John ^a  

^a ALBANY MEDICAL CENTER   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Aneurysm; Brain; Evidence based medicine; Pharmacotherapy; Stroke; Subarachnoid hemorrhage; Vasospasm

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE RECEPTOR STIMULATING AGENT; AMINOCAPROIC ACID; CLAZOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ENOXAPARIN; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM SULFATE; NIMODIPINE; PAPAVERINE; PLACEBO; PRAVASTATIN; SIMVASTATIN; TAMOXIFEN;

ABSENCE OF SIDE EFFECTS; ARTERY DILATATION; ARTERY DISEASE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRAIN ARTERY ANEURYSM; BRAIN ARTERY ANEURYSM RUPTURE; BRAIN ISCHEMIA; BRAIN OXYGEN TENSION; BRAIN PROTECTION; BRAIN VASOSPASM; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HOT FLUSH; HUMAN; HYPERREFLEXIA; INTRACRANIAL PRESSURE; KIDNEY FAILURE; KIDNEY NECROSIS; LUNG EMBOLISM; MALAISE; MENTAL INSTABILITY; MYOPATHY; NONHUMAN; OGILVIE SYNDROME; PATHOPHYSIOLOGY; REVIEW; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SMOOTH MUSCLE RELAXATION; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR AGENTS; ENOXAPARIN; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIMODIPINE; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

EID: 68249108372     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313209X382377     Document Type: Review

References (58)

1. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med 2001; 20 (Suppl. 3): S21-S34 (Pubitemid 33732964)
2. Kazda S, Towart R. Nimodipine: A new calcium antagonistic drug with a preferential cerebrovascular action. Acta Neurochir (Wien) 1982; 63 (1-4): 259-265 (Pubitemid 12066212)
3. Towart R, Perzborn E. Nimodipine inhibits carbocyclic thromboxane- induced contractions of cerebral arteries. Eur J Pharmacol 1981; 69 (2): 213-215 (Pubitemid 11221117)
4. White RP, Cunningham MP, Robertson JT. Effect of the calcium antagonist nimodipine on contractile responses of isolated canine basilar arteries induced by serotonin, prostaglandin F2 alpha, thrombin, and whole blood. Neurosurgery 1982; 10 (3): 344-348
5. Tanaka K, Gotoh F, Muramatsu F, et al. Effect of nimodipine, a calcium antagonist, on cerebral vasospasm after subarachnoid hemorrhage in cats. Arzneimittelforschung 1982; 32 (12): 1529-1534
6. Meyer FB. Calcium antagonists and vasospasm. Neurosurg Clin N Am 1990; 1 (2): 367-376
7. Philippon J, Grob R, Dagreou F, et al. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien) 1986; 82 (3-4): 110-114
8. Seiler RW, Grolimund P, Zurbruegg HR. Evaluation of the calciumantagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. A prospective transcranial Doppler ultrasound study. Acta Neurochir (Wien) 1987; 85 (1-2): 7-16
9. Buchheit F, Boyer P. Review of treatment of symptomatic cerebral vasospasm with nimodipine. Acta Neurochir Suppl (Wien) 1988; 45: 51-55
10. Kostron H, Twerdy K, Grunert V. The calcium entry blocker nimodipine improves the quality of life of patients operated on for cerebral aneurysms. A 5-year follow-up analysis. Neurochirurgia (Stuttg) 1988; 31 (5): 150-153
11. Gilsbach JM, Harders A. Early aneurysm operation and vasospasm. Intracranial Doppler findings. Neurochirurgia (Stuttg) 1985; 28 (Suppl. 1): 100-102
12. Hund E, Aschoff A, Tronnier V, et al. Nimodipine: Evidence for clinically significant gastrointestinal side-effects. Acta Neurochir (Wien) 1990; 102 (1-2): 73-75 (Pubitemid 20043298)
13. Biondi, A, Ricciardi GK, Puybasset L, et al. Intra-arterial nimodipine for the treatment of symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage: Preliminary results. AJNR Am J Neuroradiol 2004; 25 (6): 1067-1076 (Pubitemid 38765893)
14. Biondi A, Le Jean L, Puybasset L. Clinical experience of selective intra-arterial nimodipine treatment for cerebral vasospasm following subarachnoid hemorrhage. AJNR Am J Neuroradiol 2006; 27 (3): 474 (Pubitemid 44897761)
15. Firat MM, Gelebek V, Orer HS, et al. Selective intraarterial nimodipine treatment in an experimental subarachnoid hemorrhage model. AJNR Am J Neuroradiol 2005; 26 (6): 1357-1362 (Pubitemid 43733428)
16. McGirt MJ, Pradilla G, Legnani FG, et al. Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery 2006; 58 (5) 945-951 (Pubitemid 43772438)
17. Parra A, Kreiter KT, Williams S, et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: A matched controlled cohort study. Neurosurgery 2005; 56 (3): 476-484 (Pubitemid 40316367)
18. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: A phase II randomized placebo-controlled trial. Stroke 2005; 36 (8): 1627-1632 (Pubitemid 41098752)
19. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with statins on cerebral autoregulation in patients after aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006; 21 (3): E10
20. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: Results of a pilot randomized clinical trial. Stroke 2005; 36 (9): 2024-2026 (Pubitemid 41266547)
21. Wurm G, Tomancok B, Nussbaumer K, et al. Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: A double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg 2004; 106 (2): 97-103 (Pubitemid 38299271)
22. Adner M, You J, Edvinsson L. Characterization of endothelin-A receptors in the cerebral circulation. Neuroreport 1993; 4(4): 441-443 (Pubitemid 23116744)
23. Adner M, Jansen I, Edvinsson L. Endothelin-A receptors mediate contraction in human cerebral, meningeal and temporal arteries. J Auton Nerv Syst 1994; 49 (Suppl.): S117-S121 (Pubitemid 24281389)
24. Cirak B, Kiymaz N, Ari HH, et al. The effects of endothelin antagonist BQ-610 on cerebral vascular wall following experimental subarachnoid hemorrhage and cerebral vasospasm. Clin Auton Res 2004; 14 (3): 197-201 (Pubitemid 38951997)
25. Yu JC, Pickard JD, Davenport AP. Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells. Br J Pharmacol 1995; 116 (5): 2441-2446
26. Xie A, Aihara Y, Bouryi VA, et al. Novel mechanism of endothelin- 1-induced vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab 2007; 27: 1692-1701 (Pubitemid 47476098)
27. Vatter H, Zimmermann M, Tesanovic V, et al. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: Effect on endothelin(B) receptormediated relaxation. J Neurosurg 2005; 102 (6): 1108-1114 (Pubitemid 43193981)
28. Vatter H, Zimmermann M, Tesanovic V, et al. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: Inhibitory effect on endothelin(A) receptormediated contraction. J Neurosurg 2005; 102 (6): 1101-1107 (Pubitemid 43193980)
29. Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV- 034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: Results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005; 103 (1): 9-17 (Pubitemid 43193928)
30. Nibbelink DW, Torner JC, Henderson WG. Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke 1975; 6 (6): 622-629
31. Ratnoff OD. Epsilon aminocaproic acid - a dangerous weapon. N Engl J Med 1969; 280 (20): 1124-1125
32. MacKay AR, Sang UH, Weinstein PR. Myopathy associated with epsilon-aminocaproic acid (EACA) therapy. Report of two cases. J Neurosurg 1978; 49 (4): 597-601
33. Sonntag VK, Stein BM. Arteriopathic complications during treatment of subarachnoid hemorrhage with epsilon-aminocaproic acid. J Neurosurg 1974; 40 (4): 480-485
34. Knuckey NW, Stokes BA. Medical management of patients following a ruptured cerebral aneurysm, with epsilon-aminocaproic acid, kanamycin, and reserpine. Surg Neurol 1982; 17 (3): 181-185
35. Dalbasti T, Karabiyikoglu M, Ozdamar N, et al. Efficacy of controlled-release papaverine pellets in preventing symptomatic cerebral vasospasm. J Neurosurg 2001; 95 (1): 44-50 (Pubitemid 32799771)
36. Rath GP, Mukta, Prabhakar H, et al. Haemodynamic changes after intracisternal papaverine instillation during intracranial aneurysmal surgery. Br J Anaesth 2006; 97 (6): 848-850
37. Majoie CB, van Boven LJ, van de Beek D, et al. Perfusion CT to evaluate the effect of transluminal angioplasty on cerebral perfusion in the treatment of vasospasm after subarachnoid hemorrhage. Neurocrit Care 2007; 6 (1): 40-44 (Pubitemid 46424450)
38. Vajkoczy P, Horn P, Bauhuf C, et al. Effect of intra-arterial papaverine on regional cerebral blood flow in hemodynamically relevant cerebral vasospasm. Stroke 2001; 32 (2): 498-505 (Pubitemid 32155242)
39. Liu JK, Tenner MS, Gottfried ON, et al. Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm. J Neurosurg 2004; 100 (3): 414-421
40. Carhuapoma JR, Qureshi AI, Tamargo RJ, et al. Intra-arterial papaverine-induced seizures: Case report and review of the literature. Surg Neurol 2001; 56 (3): 159-163 (Pubitemid 32946846)
41. Stiefel MF, Spiotta AM, Udoetuk JD, et al. Intra-arterial papaverine used to treat cerebral vasospasm reduces brain oxygen. Neurocrit Care 2006; 4 (2): 113-118
42. Lin CL, Dumont AS, Wu SC, et al. 17beta-estradiol inhibits endothelin-1 production and attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. Exp Biol Med (Maywood) 2006; 231 (6): 1054-1057 (Pubitemid 43845577)
43. Tsang SY, Yao X, Essin K, et al. Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2z channels. Stroke 2004; 35 (7): 1709-1714 (Pubitemid 38823652)
44. Torregrosa G, Burguete MC, Pérez-Asensio FJ, et al. Pharmacological profile of phytoestrogens in cerebral vessels: In vitro study with rabbit basilar artery. Eur J Pharmacol 2003; 482 (1-3): 227-234
45. Momoi H, Ikomi F, Ohhashi T. Estrogen-induced augmentation of endothelium-dependent nitric oxide-mediated vasodilation in isolated rat cerebral small arteries. Jpn J Physiol 2003; 53 (3): 193-203 (Pubitemid 37229294)
46. Li X, Geary GG, Gonzales RJ, et al. Effect of estrogen on cerebrovascular prostaglandins is amplified inmicewith dysfunctional NOS. Am J Physiol Heart Circ Physiol 2004; 287 (2): H588-H594 (Pubitemid 38955288)
47. Ospina JA, Duckles SP, Krause DN. 17beta-estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation. Am J Physiol Heart Circ Physiol 2003; 285 (1): H241-H250
48. Kirk J Kirk K. Inhibition of volume-activated I- and taurine efflux from HeLa cells by P-glycoprotein blockers correlates with calmodulin inhibition. J Biol Chem 1994; 269 (47): 29289-29294
49. Feustel PJ, Jin Y, Kimelberg HK. Volume-regulated anion channels are the predominant contributors to release of excitatory amino acids in the ischemic cortical penumbra. Stroke 2004; 35 (5): 1164-1168
50. Osuka K, FeustelPJ, Mongin AA, et al. Tamoxifen inhibits nitrotyrosine formation after reversible middle cerebral artery occlusion in the rat. J Neurochem 2001; 76 (6): 1842-1850 (Pubitemid 32221124)
51. Obate T, Kubota S. Protective effect of tamoxifen on 1-methyl-4- phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neurosci Lett 2001; 308 (2): 87-90 (Pubitemid 32703674)
52. Zhang Y, Milatovic D, Aschner M, et al. Neuroprotection by tamoxifen in focal cerebral ischemia is not mediated by an agonist action at estrogen receptors but is associated with antioxidant activity. Exp Neurol 2007; 204 (2): 819-827 (Pubitemid 46497069)
53. Kimelberg HK, Feustel PJ, Jin Y, et al. Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. Neuroreport 2000; 11 (12): 2675-2679 (Pubitemid 30672444)
54. Zhang Y, Jin Y, Behr MJ, et al. Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia. Exp Neurol 2005; 196 (1): 41-46 (Pubitemid 41416646)
55. Boulos AS, D D, Deshaies EM, et al. Tamoxifen protects the canine brain from ischemia in an endovascular model of thromboembolic stroke. Presented at American Stroke Association International Stroke Conference, 2007, San Francisco, CA, USA
56. Wickman G, Vollrath B. Effects of tamoxifen on oxyhemoglobininduced cerebral vasoconstriction. Eur J Pharmacol 2000; 390 (1- 2): 181-184 (Pubitemid 30122452)
57. Tsang SY, Yao X, Chan FL, et al. Estrogen and tamoxifen modulate cerebrovascular tone in ovariectomized female rats. Hypertension 2004; 44 (1): 78-82 (Pubitemid 38823491)
58. Lin CL, Shih HC, Lieu AS, et al. Attenuation of experimental subarachnoid hemorrhage-induced cerebral vasospasm by the adenosine A2A receptor agonist CGS 21680. J Neurosurg 2007; 106 (3): 436-441